loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in Johnson & Johnson reports response rate for head, neck cancer treatment Oct 25, 2026, 5:53 PM ETJohnson & Johnson (JNJ) StockMRKBy: Rob Williams, SA News Editor Johnson & Johnson (JNJ) reported that its cancer drug Rybrevant Faspro, combined with immunotherapy and chemotherapy, shrank tumors in 77% of patients with certain forms of advanced head and neck cancer in an early-stage clinical trial. The findings were presented at the European To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Quick Insights If larger trials confirm early results, Rybrevant Faspro could expand from lung cancer into head and neck cancer treatment, increasing JNJ's commercial potential. In an early-stage trial, 77% of patients had confirmed tumor reduction, with some achieving complete responses, but the study lacks a comparative group. Common side effects included anemia, low albumin, reduced platelets, and mouth inflammation; injection reactions occurred in 13% but none were severe.
document fetched 2026-10-26 02:57 · canonical https://seekingalpha.com/news/4657010-johnson-and-johnson-reports-response-rate-for-head-neck-cancer-treatment?feed_item_type=news